ACTU
Price
$8.66
Change
+$0.05 (+0.58%)
Updated
Sep 4, 10:50 AM (EDT)
Capitalization
178.62M
SYRE
Price
$16.81
Change
+$0.18 (+1.08%)
Updated
Sep 3 closing price
Capitalization
1.02B
63 days until earnings call
Interact to see
Advertisement

ACTU vs SYRE

Header iconACTU vs SYRE Comparison
Open Charts ACTU vs SYREBanner chart's image
Actuate Therapeutics
Price$8.66
Change+$0.05 (+0.58%)
Volume$100
Capitalization178.62M
Spyre Therapeutics
Price$16.81
Change+$0.18 (+1.08%)
Volume$293.94K
Capitalization1.02B
ACTU vs SYRE Comparison Chart in %
Loading...
ACTU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACTU vs. SYRE commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACTU is a Hold and SYRE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (ACTU: $8.61 vs. SYRE: $16.83)
Brand notoriety: ACTU and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACTU: 89% vs. SYRE: 53%
Market capitalization -- ACTU: $178.62M vs. SYRE: $1.02B
ACTU [@Biotechnology] is valued at $178.62M. SYRE’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACTU’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • ACTU’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, ACTU is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACTU’s TA Score shows that 6 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).

  • ACTU’s TA Score: 6 bullish, 4 bearish.
  • SYRE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than ACTU.

Price Growth

ACTU (@Biotechnology) experienced а +6.96% price change this week, while SYRE (@Biotechnology) price change was -1.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.02%. For the same industry, the average monthly price growth was +6.62%, and the average quarterly price growth was +28.65%.

Reported Earning Dates

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (-0.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($1.02B) has a higher market cap than ACTU($179M). ACTU YTD gains are higher at: 8.166 vs. SYRE (-27.706). ACTU has higher annual earnings (EBITDA): -24.66M vs. SYRE (-222.15M). SYRE has more cash in the bank: 527M vs. ACTU (6.49M). ACTU (0) and SYRE (0) have equivalent revenues.
ACTUSYREACTU / SYRE
Capitalization179M1.02B18%
EBITDA-24.66M-222.15M11%
Gain YTD8.166-27.706-29%
P/E RatioN/A1.72-
Revenue00-
Total Cash6.49M527M1%
Total DebtN/A0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
10
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
82
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACTUSYRE
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 1 day ago
85%
Declines
ODDS (%)
Bearish Trend 15 days ago
90%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ACTU
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGECX10.880.05
+0.46%
Russell Inv Global Equity C
TEMUX15.890.04
+0.25%
Morgan Stanley Pathway Em Mkts Eq
WEIMX18.01N/A
N/A
TETON Westwood Mighty Mites I
CSJAX67.03N/A
N/A
Cohen & Steers Realty Shares A
GEOSX15.55-0.02
-0.13%
Pear Tree Essex Environmental Opps Ins

ACTU and

Correlation & Price change

A.I.dvisor tells us that ACTU and SYRE have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACTU and SYRE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACTU
1D Price
Change %
ACTU100%
-1.03%
SYRE - ACTU
30%
Poorly correlated
+1.20%
ERAS - ACTU
28%
Poorly correlated
-10.63%
CGON - ACTU
28%
Poorly correlated
+4.41%
IDYA - ACTU
28%
Poorly correlated
+1.10%
ABUS - ACTU
27%
Poorly correlated
+3.14%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+1.20%
IDYA - SYRE
61%
Loosely correlated
+1.10%
CGON - SYRE
61%
Loosely correlated
+4.41%
BEAM - SYRE
58%
Loosely correlated
+15.02%
XNCR - SYRE
57%
Loosely correlated
-2.57%
CRNX - SYRE
56%
Loosely correlated
+4.17%
More